7NR Retail Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 29, 2025, 7:27 pm

Quick Insight

7NR Retail Ltd, operating in the retail apparel/accessories sector, currently trades at a price of ₹4.91 with a market capitalization of ₹27.5 Cr. The company's financial metrics reveal a P/E ratio of 38.2, a low ROE of 1.14%, and a ROCE of 2.16%. With an OPM of -3.43% and a net profit of ₹0.33 Cr, the firm faces profitability challenges. Moreover, the high CCC of 194.17 days and a low P/BV ratio of 0.37x suggest inefficiencies in operations and undervaluation. The presence of borrowings at ₹4.82 Cr and a moderate ICR of 1.75x indicate a need for improved financial management. Overall, 7NR Retail Ltd shows signs of financial distress and operational inefficiencies, necessitating strategic interventions to enhance performance and investor confidence.

Competitors of 7NR Retail Ltd

All Competitor Stocks of 7NR Retail Ltd

Quarterly Result

Last Updated: August 20, 2025, 12:55 am

Below is a detailed analysis of the quarterly data for 7NR Retail Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 4.95 Cr.. The value appears to be declining and may need further review. It has decreased from 14.92 Cr. (Mar 2025) to 4.95 Cr., marking a decrease of 9.97 Cr..
• For Expenses, as of Jun 2025, the value is 5.12 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 13.79 Cr. (Mar 2025) to 5.12 Cr., marking a decrease of 8.67 Cr..
• For Operating Profit, as of Jun 2025, the value is -0.17 Cr.. The value appears to be declining and may need further review. It has decreased from 1.13 Cr. (Mar 2025) to -0.17 Cr., marking a decrease of 1.30 Cr..
• For OPM %, as of Jun 2025, the value is -3.43%. The value appears to be declining and may need further review. It has decreased from 7.57% (Mar 2025) to -3.43%, marking a decrease of 11.00%.
• For Other Income, as of Jun 2025, the value is 0.13 Cr.. The value appears to be declining and may need further review. It has decreased from 0.44 Cr. (Mar 2025) to 0.13 Cr., marking a decrease of 0.31 Cr..
• For Interest, as of Jun 2025, the value is 0.03 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.27 Cr. (Mar 2025) to 0.03 Cr., marking a decrease of 0.24 Cr..
• For Depreciation, as of Jun 2025, the value is 0.04 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.02 Cr. (Mar 2025) to 0.04 Cr., marking an increase of 0.02 Cr..
• For Profit before tax, as of Jun 2025, the value is -0.11 Cr.. The value appears to be declining and may need further review. It has decreased from 1.28 Cr. (Mar 2025) to -0.11 Cr., marking a decrease of 1.39 Cr..
• For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be increasing, which may not be favorable. It has increased from -2.34% (Mar 2025) to 0.00%, marking an increase of 2.34%.
• For Net Profit, as of Jun 2025, the value is -0.11 Cr.. The value appears to be declining and may need further review. It has decreased from 1.30 Cr. (Mar 2025) to -0.11 Cr., marking a decrease of 1.41 Cr..
• For EPS in Rs, as of Jun 2025, the value is -0.02. The value appears to be declining and may need further review. It has decreased from 0.23 (Mar 2025) to -0.02, marking a decrease of 0.25.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 3:22 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 2:02 pm

Below is a detailed analysis of the balance sheet data for 7NR Retail Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 28.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 28.01 Cr..
• For Reserves, as of Mar 2025, the value is 1.03 Cr.. The value appears strong and on an upward trend. It has increased from 0.70 Cr. (Mar 2024) to 1.03 Cr., marking an increase of 0.33 Cr..
• For Borrowings, as of Mar 2025, the value is 4.82 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 5.27 Cr. (Mar 2024) to 4.82 Cr., marking a decrease of 0.45 Cr..
• For Other Liabilities, as of Mar 2025, the value is 6.70 Cr.. The value appears to be improving (decreasing). It has decreased from 9.33 Cr. (Mar 2024) to 6.70 Cr., marking a decrease of 2.63 Cr..
• For Total Liabilities, as of Mar 2025, the value is 40.56 Cr.. The value appears to be improving (decreasing). It has decreased from 43.31 Cr. (Mar 2024) to 40.56 Cr., marking a decrease of 2.75 Cr..
• For Fixed Assets, as of Mar 2025, the value is 0.81 Cr.. The value appears strong and on an upward trend. It has increased from 0.61 Cr. (Mar 2024) to 0.81 Cr., marking an increase of 0.20 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Mar 2025, the value is 0.68 Cr.. The value appears to be declining and may need further review. It has decreased from 1.64 Cr. (Mar 2024) to 0.68 Cr., marking a decrease of 0.96 Cr..
• For Other Assets, as of Mar 2025, the value is 39.07 Cr.. The value appears to be declining and may need further review. It has decreased from 41.06 Cr. (Mar 2024) to 39.07 Cr., marking a decrease of 1.99 Cr..
• For Total Assets, as of Mar 2025, the value is 40.56 Cr.. The value appears to be declining and may need further review. It has decreased from 43.31 Cr. (Mar 2024) to 40.56 Cr., marking a decrease of 2.75 Cr..

However, the Borrowings (4.82 Cr.) are higher than the Reserves (1.03 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Key Financial Ratios

After reviewing the key financial ratios for 7NR Retail Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 0.12. This value is below the healthy minimum of 5. It has increased from -0.04 (Mar 24) to 0.12, marking an increase of 0.16.
• For Diluted EPS (Rs.), as of Mar 25, the value is 0.12. This value is below the healthy minimum of 5. It has increased from -0.04 (Mar 24) to 0.12, marking an increase of 0.16.
• For Cash EPS (Rs.), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 3. It has increased from -0.29 (Mar 24) to 0.04, marking an increase of 0.33.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 10.37. It has increased from 10.25 (Mar 24) to 10.37, marking an increase of 0.12.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 10.37. It has increased from 10.25 (Mar 24) to 10.37, marking an increase of 0.12.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 7.67. It has increased from 4.15 (Mar 24) to 7.67, marking an increase of 3.52.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 2. It has increased from -0.26 (Mar 24) to 0.19, marking an increase of 0.45.
• For PBIT / Share (Rs.), as of Mar 25, the value is 0.26. This value is within the healthy range. It has increased from -0.36 (Mar 24) to 0.26, marking an increase of 0.62.
• For PBT / Share (Rs.), as of Mar 25, the value is 0.15. This value is within the healthy range. It has increased from -0.41 (Mar 24) to 0.15, marking an increase of 0.56.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 0.11. This value is below the healthy minimum of 2. It has increased from -0.39 (Mar 24) to 0.11, marking an increase of 0.50.
• For PBDIT Margin (%), as of Mar 25, the value is 2.49. This value is below the healthy minimum of 10. It has increased from -6.47 (Mar 24) to 2.49, marking an increase of 8.96.
• For PBIT Margin (%), as of Mar 25, the value is 3.41. This value is below the healthy minimum of 10. It has increased from -8.83 (Mar 24) to 3.41, marking an increase of 12.24.
• For PBT Margin (%), as of Mar 25, the value is 1.98. This value is below the healthy minimum of 10. It has increased from -9.98 (Mar 24) to 1.98, marking an increase of 11.96.
• For Net Profit Margin (%), as of Mar 25, the value is 1.52. This value is below the healthy minimum of 5. It has increased from -9.58 (Mar 24) to 1.52, marking an increase of 11.10.
• For Return on Networth / Equity (%), as of Mar 25, the value is 1.12. This value is below the healthy minimum of 15. It has increased from -3.88 (Mar 24) to 1.12, marking an increase of 5.00.
• For Return on Capital Employeed (%), as of Mar 25, the value is 2.17. This value is below the healthy minimum of 10. It has increased from -3.03 (Mar 24) to 2.17, marking an increase of 5.20.
• For Return On Assets (%), as of Mar 25, the value is 0.80. This value is below the healthy minimum of 5. It has increased from -2.57 (Mar 24) to 0.80, marking an increase of 3.37.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.16. This value is below the healthy minimum of 0.2. It has decreased from 0.17 (Mar 24) to 0.16, marking a decrease of 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.16. This value is within the healthy range. It has decreased from 0.18 (Mar 24) to 0.16, marking a decrease of 0.02.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.51. It has increased from 0.25 (Mar 24) to 0.51, marking an increase of 0.26.
• For Current Ratio (X), as of Mar 25, the value is 5.77. This value exceeds the healthy maximum of 3. It has increased from 4.49 (Mar 24) to 5.77, marking an increase of 1.28.
• For Quick Ratio (X), as of Mar 25, the value is 4.96. This value exceeds the healthy maximum of 2. It has increased from 4.15 (Mar 24) to 4.96, marking an increase of 0.81.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 1.75. This value is below the healthy minimum of 3. It has increased from -5.65 (Mar 24) to 1.75, marking an increase of 7.40.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.07. This value is below the healthy minimum of 3. It has increased from -7.37 (Mar 24) to 2.07, marking an increase of 9.44.
• For Enterprise Value (Cr.), as of Mar 25, the value is 15.34. It has decreased from 19.10 (Mar 24) to 15.34, marking a decrease of 3.76.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.71. This value is below the healthy minimum of 1. It has decreased from 1.64 (Mar 24) to 0.71, marking a decrease of 0.93.
• For EV / EBITDA (X), as of Mar 25, the value is 28.62. This value exceeds the healthy maximum of 15. It has increased from -25.39 (Mar 24) to 28.62, marking an increase of 54.01.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.51. This value is below the healthy minimum of 1. It has decreased from 1.20 (Mar 24) to 0.51, marking a decrease of 0.69.
• For Price / BV (X), as of Mar 25, the value is 0.37. This value is below the healthy minimum of 1. It has decreased from 0.48 (Mar 24) to 0.37, marking a decrease of 0.11.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.51. This value is below the healthy minimum of 1. It has decreased from 1.20 (Mar 24) to 0.51, marking a decrease of 0.69.
• For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -0.07 (Mar 24) to 0.02, marking an increase of 0.09.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness